Session 20

Frontotemporal Dementia

The frontotemporal dementia (FTD) is of six types involving the frontal or temporal lobes such as behavioral variant of frontotemporal dementia, semantic variant primary progressive aphasia, nonfluent agrammatic variant primary progressive aphasia, corticobasal syndrome, progressive supranuclear palsy, and frontotemporal dementia associated with motor neuron disease. One variant is the clinical presentation of frontotemporal lobar degeneration, which is characterized by progressive neuronal loss predominantly involving the frontal or temporal lobes, and typical loss of over 70% of spindle neurons, while other neuron types remain intact. Common signs and symptoms include significant changes in social and personal behavior, apathy, blunting of emotions, and deficits in both expressive and receptive language. There is no cure for FTD at present but treatments do help alleviate symptoms. This session discusses more about frontotemporal dementia.

Session 19

Dementia with Lewy Bodies

Dementia with Lewy bodies is a type of dementia caused by changes in behavior, cognition and movement. Memory loss is not always present early. Dementia steadily worsens over time and the condition is diagnosed when cognitive decline interferes with normal daily functioning. A core feature is REM sleep behavior disorder (RBD), in which individuals lose normal muscle paralysis during REM sleep, and act out their dreams. RBD may appear years or decades before other symptoms. Other frequent symptoms include visual hallucinations; marked fluctuations in attention or alertness; and slowness of movement, trouble in walking, or rigidity. The autonomic nervous system is usually affected, resulting in changes in blood pressure, heart and gastrointestinal function, with constipation as a common symptom. Mood changes such as depression and apathy are common. This session further discusses more about Dementia with Lewy bodies.

Session 18

Alzheimer’s Pathophysiology

Alzheimer’s disease is pathologically characterized by intracellular neurofibrillary tangles and extracellular amyloidal protein deposits contributing to senile plaques. Over the last two decades, advances in the field of pathogenesis have inspired the researchers for the investigation of novel pharmacological therapeutics centered more towards the pathophysiological events of the disease. While the neuropathological features of Alzheimer’s disease are recognized but the intricacies of the mechanism have not been clearly defined. This lack of understanding regarding the pathogenic process may be the likely reason for the non-availability of effective treatment which can prevent onset and progression of the disease. Owing to the important progress in the field of pathophysiology in the last couple of years, new therapeutic targets are available that should render the underlying disease process to be tackled directly. This session discusses more about Alzheimer’s pathophysiology.

Session 17

Advances in Alzheimer’s Therapy

Late investigations demonstrating that helpful medications and quality treatment are propelled procedures to control Alzheimer’s sickness Genomics treatment is latest advances in AD look into, when the malady was first portrayed. Specialists are searching for new treatment medications for dementia. As of now, there is no cure for Alzheimer’s but these Alzheimer’s items may demonstrate decent outcomes to cure memory misfortune.

Session 16

Amyloid Protein in Alzheimer’s and Dementia

Alzheimer’s sickness (AD), the main source of dementia around the world, is portrayed by the collection of the β-amyloid peptide (Aβ) inside the cerebrum alongside hyperphosphorylated and cut types of the microtubule-related protein tau.
Amyloid Imaging
Amyloid Immunotherapy

Session 15

Animal Models in Dementia

The creature models of dementia and Alzheimer’s sickness for pre-clinical testing and clinical interpretation. Dementia is a clinical disorder with anomalous level of memory misfortune and disabled capacity to review occasions from the past regularly described by Alzheimer’s malady.
Neurobehavioral Toxicology Testing
Pre-clinical testing and clinical interpretation
Protein-protein collaborations
Hereditary qualities of translational models
Creature models of human intellectual maturing

Session 14

Neurological Disorders

Neurological scatters are ailments of the mind, spine and the nerves that associate them. There are in excess of 600 sicknesses of the sensory system, for example, mind tumors, epilepsy, Parkinson’s ailment and stroke and less natural ones, for example, front fleeting dementia.

Session 13

Alzheimer’s Products & Market Analysis

A few items are accessible in the market to control ailment. These Products are Color Cards Activity, Color-Coded Therapy are intended to invigorate the psyche and sense. Alzheimer’s diversions and riddles and eating dishes are accessible in the market for mind movement. Treatment with sedate, non-medication or pharmaceutical and surgery once in a while indicates side effects. But these Alzheimer’s items may demonstrate a decent outcomes to cure memory misfortune.

Session 12

Alzheimer’s Medicine

Medication and non-Drug treatment for Alzheimer’s sickness is essential to cure some behavioral side effects. Medications like Acetyl cholinesterase Inhibitors and NMDA receptor opponents used to treat Alzheimer’s malady control Non sedate treatment like workmanship treatment, aromatic healing and religious exercises may control passionate and push responses. The present Herbal solution, dietary supplements and therapeutic sustenance’s are utilized as elective treatment for Alzheimer’s sickness.

Session 11

Dementia Care Management

Dementia Care Management can be a challenging one as it requires lot of patience in handling people with dementia. The families, friends and others need to participate in care management processes and help the care giver, the much needed support. Monitoring health and behavioral patterns, improving the cognitive abilities, the language, strengthening their memory powers, helping them perform simple tasks on their own etc. are some of the most challenging tasks that require infinite patience, care and love towards these people with dementia. This session discusses further innovative strategies that need to be adopted in dementia care management processes.

Session 10

Cognitive Stimulation Therapy

Cognitive Stimulation Therapy (CST) is a program of activities that are carried out for a certain period of length by forming small groups consisting of 5 to 8 people by a trained specialist nurse or a caregiver or occupational therapist. Cognitive Stimulation Therapy aims to improve the mental abilities and memory in people with dementia. There is substantial proof that Cognitive Stimulation Therapy is just as beneficial as drug treatments for the symptoms of dementia. Such programs are carried out in nursing homes, healthcare communities, day centers, clinical facilities and are conducted by a trained professional nurse, or caregiver, or occupational therapist. This session discuses how best cognitive stimulation therapy programs be enhanced and made more impactful in order to derive maximum benefits for people having dementia.

Session 9


Neuropharmacology deals with the study of how drugs affect cellular function in the nervous system and the neural mechanisms that impacts behavior. There are two main branches of neuropharmacology, which are behavioral and molecular. Behavioral neuropharmacology focuses on the study of how drugs affect human behavior (neuropsychopharmacology), the drug dependence and addiction affecting the human brain. While molecular neuropharmacology involves the study of neurons and their neurochemical interactions with an overall goal of developing drugs having beneficial effects on neurological function. Both fields are interconnected with the interactions of neurotransmitters, neuropeptides, neurohormones, neuromodulators, enzymes, second messengers, co-transporters, ion channels, and receptor proteins in the central and peripheral nervous systems. This session discusses further about the research studies, and the drug development processes that treat many different neurological disorders, including pain, neurodegenerative diseases such as Parkinson’s disease and Alzheimer’s disease, psychological disorders, addiction, and many others.

Session 8

Alzheimer’s disease Imaging

Researchers take a gander at the cerebrum’s dark issue when examining about Alzheimer’s malady. A new report, found that declining white issue in the mind could be an early marker of sickness. An examination was distributed in Radiology which presumes that white issue assumes a vital part in how the sickness strikes and advances. Anomalous stores of proteins that shape amyloid plaques and tau tangles everywhere throughout the mind in Alzheimer’s illness. It can likewise be portrayed by shrinkage of mind tissues because of neurons misfortune.

This session incorporates Amyloid and Tau imaging, Imaging creature models, Imaging and hereditary qualities, New strategies in imaging, Structural and practical MRI, Positron outflow tomography, MR spectroscopy, EEG and mind mapping, SPECT imaging, Imaging connects of clinical, psychological and biomarker factors.
Registered tomography
Neuroimaging strategies
Practical MRI (fMRI)8)

Session 7

Alzheimer’s Clinical Trials and Studies

Clinical trials for Alzheimer’s sickness has turned into an unquestionable requirement, as there can’t be better medicines, better preventive techniques unless individuals volunteer to wind up subjects for clinical trials. Clinical trials are investigate contemplates led on individuals to decide if medicines are sheltered and compelling. Without clinical trials and research ponders and without human volunteers it is close difficult to discover cure for dementia and Alzheimer’s sickness. This session talks about how imperative clinical trials are without any authoritative cure for dementia and Alzheimer’s ailment.

Session 6

Therapeutic Targets

Therapeutic target refers to biological target, a protein or nucleic acid whose activity can be modified by an external stimulus. Alzheimer’s dementia is increasingly being recognized as one of the most important medical and social problems in the elderly across the world. An improved understanding of the pathogeneses of Alzheimer’s dementia has now led to the identification of numerous therapeutic targets designed to alter amyloid β protein or tau accumulation. Targeting these might likely to have significant disease-modifying effects. Further studies are still going on for Alzheimer’s dementia in phase I, II, and III trials. This session discuss the latest research studies on therapeutic targets that are going on across the world for dementia and Alzheimer’s disease.

Session 5

Care Practice and Awareness

Awareness of dementia and the care practice plays a key role in treating patients suffering from dementia and Alzheimer’s disease. Care needs should be identified first, the standardized care plans must be charted out, identify problem areas, determine goals, educate families, teach problem-solving strategies, and provide clinical support, and link families to home and community-based services. The care practice should be family-centered approach. These care practice methods should be based on the changing needs of the patient. Personalized care and relationship building is of utmost importance in care practices. Depending on the intensity and severity of the disease care practices should be strategized. This session discusses many such issues relating to care practices and awareness programs etc.

Session 4

Geriatrics and Cognitive Disorder

Geriatrics is concerned with diseases such as cognitive disorders that occur in older people generally over the age of 60. Geriatrics focuses its attention on such cognitive disorders occurring in old age people over 60 years. Right diagnosis of cognitive disorders is made difficult due to the fact that similar symptoms are associated with old age disorders and diseases. Some of the most common symptoms leading to dementia are difficulty performing tasks, disorientation of time and place, poor judgment, personality changes; becoming irritable, fearful, suspicious, and tremors etc. This session focuses its attention on the studies of Geriatrics and the cognitive diseases and how best they could manage to cure these diseases.

Session 3

PathoPhysiology and Disease Mechanisms

Pathophysiology is an integrated study of pathology and physiology combined. Pathology describes the conditions observed during the state of a disease, whereas physiology describes the processes or mechanisms operating within an organism. Pathology describes abnormal condition while pathophysiology explains the physiological mechanisms or processes whereby such conditions develops and progresses. The study of functional changes that complements with a particular disease is called pathophysiology.

Session 2

Alzheimer’s Disease: Diagnosis and Symptoms

Alzheimer’s is caused by mind cell demise. It is a neurological issue in which the passing of mind cells causes memory misfortune and intellectual decay. The aggregate size of the cerebrum shrivels in Alzheimer’s, nerve cells and associations in the tissue dynamically diminished, which can’t be seen or tried in the living mind influenced by Alzheimer’s infection, after death/examination will dependably demonstrate minor considerations in the nerve tissues, called as plaques and tangles. Plaques are found between the withering cells in the mind – from the development of a protein called beta (amyloid plaques). The tangles exist in the cerebrum neurons, from a crumbling of second protein, called tau.
Around the world, with Dementia or Related issue about 44 million individuals have endured in 2015,past outcomes indicated 35.66 million populace lived with dementia worldwide in year 2010, with numbers anticipated that would almost twofold every twenty years, to 65.7 million out of 2030 and 115.4 million of every 2050. In 2010, fifty-eight for each penny of all populace with dementia lived in nations with lower or direct earnings, with this extent foreseen to ascend to 63% till 2030 and 71% by 2050. This condition is expected to twofold by 2030 and very triple by 2050 to 115 million.
In this track we can talk about on Neurological changes in cerebrum, Amyloid protein, Genetic affiliations and helplessness qualities, Role of Apo lipoprotein E, Brain injury, Metabolic disorder and Alzheimer’s infection, Protein misfolding, total and danger, Disease-causing transformations, Epidemiology and predominance, Histone alteration, DNA methylation, Alzheimer’s illness avoidance.3)

Session 1

Alzheimer’s disease and Dementia

Alzheimer’s disease is a neurological disorder in which the death of brain cells causes memory loss and cognitive decline. The total size of the brain shrinks in Alzheimer’s, nerve cells and connections in the tissue progressively reduced, which cannot be seen or tested in the living brain affected by Alzheimer’s disease. Plaques are found between the dying cells in the brain. Symptoms usually develop slowly and get worse over time becoming severe enough to interfere with daily tasks. Alzheimer’s is the most common form of dementia. Alzheimer’s disease accounts for 60 to 80 percent of dementia cases in the world. This session focuses its attention on Alzheimer’s and dementia and the research and treatment interventions for dementia and Alzheimer’s.

Session 33

Causes And Prevention Of Alzheimer’s

While there is no known cause for Alzheimer’s disease, some research studies have indicated that the following factors may play an important role in the development of the condition such as genetic factors, the presence of or changes to certain genes; environmental factors, long-term exposure to some environmental solvents like pesticides, glues and paints or infection with certain viruses or bacteria; lifestyle factors, such as a lack of exercise, poor-quality sleep and a diet lacking fruit and vegetables. Regular physical activity and exercise may have a general protective effect on brain health and may slow progression of Alzheimer’s disease. Although there are no specific dietary specifications for Alzheimer’s, a Mediterranean-style diet like plant foods such as vegetables, fruits, beans, whole grains, nuts, olives and olive oil, along with some cheeses, yoghurt, fish, poultry and eggs may reduce the risk of Alzheimer’s disease.

Session 32

Drug Development in Dementia

Dementia is a progressive, irreversible decline in cognition that, by definition, impacts on a patient pre-existing level of functioning. The clinical syndrome of dementia has several aetiologias of which Alzheimer’s disease (AD) is the most common. Drug development in AD is based on evolving pathophysiological theory. Disease modifying approaches include the targeting of amyloid processing, aggregation of tau, insulin signaling, neuroinflammationand neurotransmitter dysfunction, with efforts thus far yielding abandoned hopes and on-going promise. Reflecting its dominance on the pathophysiological stage the amyloid cascade is central to many of the emerging drug therapies.

Session 31

Parkinson’s diseases

Parkinson’s disease (PD) is a chronic and progressive movement disorder, meaning that symptoms continue and worsen over time. Nearly one million people in the US are living with Parkinson’s disease. The cause is unknown, and although there is presently no cure, there are treatment options such as medication and surgery to manage its symptoms.

Session 30

Brain diseases

The brain is body’s control center. It’s part of the nervous system, which also includes the spinal cord and a large network of nerves and neurons. Together, the nervous system controls everything from your five senses to the muscles throughout your body. When your brain is damaged, it can affect many different things, including your memory, your sensation, and even your personality. Brain disorders include any conditions or disabilities that affect your brain. This includes those conditions that are caused by illness, genetics, or traumatic injury.

Session 29

Geriatrics and Cognitive Disorder

Geriatrics is concerned with diseases such as cognitive disorders that occur in older people generally over the age of 60. Geriatrics focuses its attention on such cognitive disorders occurring in old age people over 60 years. Right diagnosis of cognitive disorders is made difficult due to the fact that similar symptoms are associated with old age disorders and diseases. Some of the most common symptoms leading to dementia are difficulty performing tasks, disorientation of time and place, poor judgment, personality changes; becoming irritable, fearful, suspicious, and tremors etc. This session focuses its attention on the studies of Geriatrics and the cognitive diseases and how best they could manage to cure these diseases.

Session 28

Traumatic Brain Injury

Traumatic brain injury (TBI) is an injury having a wide range of symptoms and disabilities. Its effects are devastating on the person and his immediate family members. A brain injury is mild if loss of consciousness and/or confusion and disorientation is less than 30 minutes. MRI and CAT scans may not show anything, but the person may have cognitive problems like headache, mood swings and frustration, difficulty thinking, memory problems, and attention deficits. This session discusses various causes and symptoms, the diagnosis procedures and the treatment for traumatic brain injury.

Session 27


Neuroimmunology is a field joining neuroscience, the investigation of the sensory system, and immunology, the investigation of the immune system. Neuroimmunologists look to more readily comprehend the connections of these two complex frameworks amid improvement, homeostasis, and reaction to wounds. A long haul objective of this quickly creating examination zone is to additionally build up our comprehension of the pathology of certain neurological sicknesses, some of which have no reasonable etiology. In doing as such, neuroimmunology adds to the advancement of new pharmacological medications for a few neurological conditions. Numerous kinds of cooperations include both the apprehensive and invulnerable frameworks including the physiological working of the two frameworks in wellbeing and sickness, glitch of either or potentially the two frameworks that prompts issue, and the physical, compound, and ecological stressors that influence the two frameworks every day.

Session 26

Diseases Associated with Dementia

Dementia is a term used to describe severe changes in the brain that causes memory loss. Diseases associated with dementia are many, which include Alzheimer’s disease – which is the most common type of dementia; Vascular dementia – which is caused by a lack of blood flow to the brain and can happen as you age and can be related to atherosclerotic disease or stroke; dementia with Lewy bodies – which is caused by protein deposits in nerve cells, this interrupts chemical messages in the brain and causes memory loss and disorientation; Frontotemporal dementia – affect the front and side parts of the brain, which are the areas that control language and behavior; Parkinson’s disease, Creutzfeldt-Jakob disease, Wernicke-Korsakoff syndrome and many others. This session discusses more about diseases associated with dementia.

Session 25

Posterior Cortical Atrophy

Posterior Cortical Atrophy (PCA) is a neurodegenerative condition characterized by progressive, often dramatic and relatively selective decline in visual processing skills and other functions sub-served by parietal, occipital and occipital-temporal regions. Age of onset is typically between 50–65 years and the syndrome is associated with a variety of underlying pathologies. Posterior Cortical Atrophy has been recognized for more than two decades and yet the condition is relatively neglected by researchers. Patients often experience a considerable delay in the time to diagnosis owing to the young age of onset and unusual presenting symptoms. In addition the term PCA has been applied inconsistently, making it difficult to draw comparisons across studies. This session discusses more about Posterior Cortical Atrophy (PCA).

Session 24

Awareness and Care Practices

Dementia patients need assistance and full time care as much as drugs. Some common care practices in Dementia are assistance in food and fluid consumption, pain management, social engagement ensuring safety and security of Dementia patients, understanding patient’s mood changes, particular behavior, speech problems and help in rectifying them. Main aim of care practices is to ensure cut in hospitalization and psychotropic drugs. Dementia patients need end of life care, so qualified nursing staff is needed. Few care practices which are used are indoor and outdoor activities, visual and audio stimulation, Art therapy. There should be a wide awareness among the public and societies about dementia care practices and awareness. This session discusses more about dementia care practice and awareness.

Session 23

Causes and Risk Factors

Causes and Risk Factors of Alzheimer’s Disease and Dementia are old age, family history, hereditary causes, and other habits such as unhealthy lifestyle. It has been estimated that up to half of the cases of Alzheimer’s disease worldwide may be the result of seven key modifiable risk factors such as diabetes, head injuries, high blood pressure, obesity, smoking, depression, cognitive inactivity or Low levels of formal education, and lack of physical activity etc. This session discusses more about causes and risk factors causing Alzheimer’s disease and dementias.

Session 22

Therapeutic Targets & Mechanisms for Treatment

Recent research findings have led to greater understanding of disease neurobiology in Alzheimer’s disease and identification of unique targets for drug development. Current therapeutic options aim at transmitter targets secondary to Alzheimer’s disease pathology. The next generation of drugs for Alzheimer’s disease will alter the underlying disease course and or provide greater symptomatic benefit. Targets for these drugs were identified in the study of Alzheimer’s disease pathophysiology and include molecular events that result in the production and accumulation of the amyloid beta (Aβ) protein in neurotic plaques and hyper phosphorylation, condensation and aggregation of the microtubule-associated protein tau in neurofibrillary tangles (NFTs). This session discusses more about therapeutic targets and mechanisms for treatment.

Session 21

Mixed Dementia

Mixed dementia is common among the people suffering with dementia. Mixed dementia is nothing but combination of two or more types of dementia. A number of combinations are possible. For example, some people have both Alzheimer’s disease and vascular dementia. Some studies indicate that mixed dementia is the most common cause of dementia in the elderly. For example, autopsy studies looking at the brains of people who had dementia indicate that most people age 80 and older probably had mixed dementia caused by a combination of brain changes related to Alzheimer’s disease, vascular disease-related processes, or another neurodegenerative condition. However, in a person with mixed dementia, it may not be clear exactly how many of a person’s symptoms are due to Alzheimer’s or another disease. This session discusses more about mixed dementia,

Session 35

Vascular Dementia

Vascular dementia is a general term describing problems with reasoning, planning, judgment, memory and other thought processes caused by brain damage from impaired blood flow to the brain. Vascular dementia, also known as multi-infarct dementia (MID) and vascular cognitive impairment (VCI), is dementia caused by problems in the supply of blood to the brain, typically a series of minor strokes, leading to worsening cognitive decline that occurs step by step. The term refers to a syndrome consisting of a complex interaction of cerebrovascular disease and risk factors that lead to changes in the brain structures due to strokes and lesions, and resulting changes in cognition. The temporal relationship between a stroke and cognitive deficits is needed to make the diagnosis.

Session 34

Animal Models And Translational Medicine

Translational Medicine and Research & Clinical seeks to bridge the full scope of explorations between basic research on drug discovery and clinical studies, validating putative therapies for aging-related chronic brain conditions that affect cognition, motor functions, and other behavioral or clinical symptoms associated with all forms dementia and Alzheimer’s disease. The forms of interventions that are of special interest include drugs, biologics, devices, and psychotherapeutic, psychosocial, and non-pharmacological modalities. Translational medicine deals with broad array of approaches to research such as discovery, related-early protein chemistry, cell biology, preclinical studies, mechanistic exploratory therapeutic animal models, therapeutic development, clinical pharmacology, and the application of neuropsychology, clinical ratings, clinical trials methods, neuroimaging, biomarkers, clinical research informatics, and other interdisciplinary approaches relevant to clinical therapeutics and outcomes.